Loss of dysbindin-1, a risk gene for schizophrenia, leads to impaired group 1 metabotropic glutamate receptor function in mice by Sanjeev K. Bhardwaj et al.
ORIGINAL RESEARCH
published: 26 March 2015
doi: 10.3389/fnbeh.2015.00072
Loss of dysbindin-1, a risk gene for
schizophrenia, leads to impaired
group 1 metabotropic glutamate
receptor function in mice
Sanjeev K. Bhardwaj , Richard T. Ryan , Tak Pan Wong and Lalit K. Srivastava *
Department of Psychiatry and Integrated Programme in Neuroscience, Douglas Mental Health University Institute, McGill
University, Montreal, QC, Canada
Edited by:
Jozsef Haller,






University of Melbourne, Australia
*Correspondence:
Lalit K. Srivastava,
Department of Psychiatry and
Integrated Programme in
Neuroscience, Douglas Mental
Health University Institute, McGill
University, 6875 LaSalle Boulevard,
Montreal, QC, H4H1R3, Canada
lalit.srivastava@mcgill.ca
Received: 30 December 2014
Accepted: 06 March 2015
Published: 26 March 2015
Citation:
Bhardwaj SK, Ryan RT, Wong TP and
Srivastava LK (2015) Loss of
dysbindin-1, a risk gene for
schizophrenia, leads to impaired
group 1 metabotropic glutamate
receptor function in mice.
Front. Behav. Neurosci. 9:72.
doi: 10.3389/fnbeh.2015.00072
The expression of dysbindin-1, a protein coded by the risk gene dtnbp1, is reduced
in the brains of schizophrenia patients. Evidence indicates a role of dysbindin-1 in
dopaminergic and glutamatergic transmission. Glutamatergic transmission and plasticity
at excitatory synapses is critically regulated by G-protein coupled metabotropic
glutamate receptor (mGluR) family members, that have been implicated in schizophrenia.
Here, we report a role of dysbindin-1 in hippocampal group 1 mGluR (mGluRI) function
in mice. In hippocampal synaptoneurosomal preparations from sandy (sdy) mice, that
have a loss of function mutation in dysbindin-1 gene, we observed a striking reduction
in mGluRI agonist [(S)-3, 5-dihydroxyphenylglycine] (DHPG)-induced phosphorylation of
extracellular signal regulated kinase 1/2 (ERK1/2). This mGluR-ERK1/2 deficit occurred
in the absence of significant changes in protein levels of the two members of the mGluRI
family (i.e., mGluR1 and mGluR5) or in another mGluRI signaling pathway, i.e., protein
kinase C (PKC). Aberrant mGluRI-ERK1/2 signaling affected hippocampal synaptic
plasticity in the sdy mutants as DHPG-induced long-term depression (LTD) at CA1
excitatory synapses was significantly reduced. Behavioral data suggest that the mGluRI
hypofunction may underlie some of the cognitive abnormalities described in sdy mice
as the administration of CDPPB (3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl benzamide),
a positive allosteric modulator of mGluR5, rescued short-term object recognition and
spatial learning and memory deficits in these mice. Taken together, our data suggest a
novel role of dysbindin-1 in regulating mGluRI functions.
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Introduction
The dystrobrevin binding protein 1 (dtnbp1) gene, coding for dysbindin-1 protein, was
one of the first candidate risk genes reported for schizophrenia (Straub et al., 2002).
Notably, genetic association studies reveal that variations in the DTNBP1 are associated
with prefrontal cortical functions in schizophrenia patients as well as performances in
episodic and working memories in healthy subjects (Burdick et al., 2007; Fallgatter et al.,
2010; Zhang et al., 2010). The link between dysbindin-1 and cognition is interesting given
that cognitive deficits in schizophrenia are widely considered to be the core symptoms
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for which no adequate treatment strategy is available (Kalkstein
et al., 2010). The evidence from human genetic studies is
strengthened by post-mortem data showing reductions in
dysbindin-1 protein and mRNA in the hippocampus and
prefrontal cortex (PFC) of schizophrenia brains (Weickert et al.,
2008; Tang et al., 2009a). Dysbindin-1 is widely expressed
in the brain; in the hippocampus, dysbindin-1 protein is
expressed in the cell body, dendrites and spines of CA1, CA2/3
pyramidal neurons as well as in a subset of interneurons
(Talbot et al., 2009).
In diverse cells, dysbindin-1 binds to proteins in a complex
known as the biogenesis of lysosome-related organelle complex-1
(BLOC-1) which plays a role in protein trafficking in endosomal-
lysosomal system (Li et al., 2003; Ghiani et al., 2010). Knowledge
of in vivo neural functions of dysbindin-1 has mainly come
from studies in sandy (sdy) mice that have a natural autosomal
recessive mutation in dtnbp1 gene causing a loss of dysbindin-1
protein expression (Swank et al., 1991). Studies from ours and
other groups reveal that dysbindin deficiency in sdy mice leads
to a number of cognitive and social behavioral impairments,
e.g., deficits in spatial and working memory (Cox et al., 2009;
Jentsch et al., 2009; Karlsgodt et al., 2011), object recognition
memory (Bhardwaj et al., 2009), fear memory (Bhardwaj et al.,
2009), and social interaction (Hattori et al., 2008). Evidence
points to an important role of dysbindin-1 in dopaminergic as
wells as glutamatergic synaptic transmission (Jentsch et al., 2009;
Ji et al., 2009; Karlsgodt et al., 2011; Papaleo et al., 2012). For
example, reductions in presynaptic glutamate release probability
and a decrease in NMDA receptor mediated currents in the PFC
of sdy mice have been reported (Tang et al., 2009b; Karlsgodt
et al., 2011). On the other hand, in the hippocampus, NMDA
NR2A-containing NMDA receptor mediated current and long-
term potentiation (LTP) were found to be increased in sdy mice
(Tang et al., 2009b). The behavioral significance of glutamatergic
abnormalities in the dysbindin-deficient mice are, however,
unclear.
Glutamatergic synaptic transmission is mediated by a set
of fast ionotropic receptors (NMDA, AMPA and Kainate)
as well as three families of G-protein coupled metabotropic
glutamate receptors (mGluRI, II and III) (Ferraguti et al., 2008;
Niswender and Conn, 2010). The mGluRI family, that includes
closely related mGluR1 and mGluR5 subtypes are important
slow-paced modulators of fast ionotropic glutamate receptors
and synaptic plasticity (Gladding et al., 2009; Mukherjee and
Manahan-Vaughan, 2013). Intracellular signaling by mGluRI
family involves activation of classical Gq/G11- phospholipase Cβ
pathway, resulting in the mobilization of intracellular calcium
and activation of protein kinase C (PKC). In addition, mGluRIs
also activate mitogen-activated protein kinase (MAPK) signaling
including activation of extracellular signal regulated kinase 1/2
(ERK1/2) (Niswender and Conn, 2010). The mGluRI receptors
are known to play important roles in learning, memory, and
emotional behaviors (Conquet et al., 1994; Lu et al., 1997; Fowler
et al., 2011).
A primary deficit in glutamate NMDA receptor-mediated
transmission is the mainstay of glutamatergic hypothesis of
schizophrenia (Coyle, 2012). However, the reported findings
of altered mGluR1 expression in post-mortem schizophrenia
brains and the clinical success of a group II mGluR agonist in
the treatment of schizophrenia suggest a potentially important
role of mGluRs in schizophrenia (Patil et al., 2007; Volk
et al., 2010). Here, we worked on the hypothesis that the
behavioral phenotype of dysbindin-deficient sdy mice is related
to altered glutamatergic transmission through mGluRs. Our
data show that dysbindin-1 deficiency leads to a marked
reduction in a specific signaling pathway of mGluRI, and is
associated with an abnormal hippocampal synaptic plasticity
in sdy mice. Furthermore, enhancing mGluR5 function
through a positive allosteric modulator (PAM) rescued
object recognition and spatial learning and memory deficit
of sdy mice, suggesting an important role of the group 1




S-DHPG [(S)-3, 5-dihydroxyphenylglycine] and CDPPB (3-
cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl) benzamide), were
purchased from Tocris Bioscience (Ellisville, MO). Polyclonal
antibodies against total-ERK 1/2 (Cat#9102) phospho-ERK1/2
(phosphorylated at Thr202 and Tyr204 of Erk1;Thr185
and Tyr187 of Erk2, Cat#9101), and phospho-PKC (Pan)
(autophosphorylated at carboxy terminal Ser660 residue; Cat
#9371) were from Cell Signaling (Beverly, Massachusetts, USA).
Monoclonal antibody against mGluR1 was purchased from BD
Transduction (Franklin Lakes, NJ). Polyclonal antibody for
mGluR5 was obtained from Upstate Biotechnology (Lake Placid,
NY). Antibody against the housekeeping protein β-actin was
from Sigma (St. Louis, Missouri, USA). All other materials were
purchased from commercial sources.
Animals
The experiments, approved by the Animal Care and Use
Committee of the Douglas Hospital Research Centre, were
carried out in accordance with the guidelines of the Canadian
Council of Animal Care. The sdy mutation, originally on
DBA/2J strain (Swank et al., 1991) was transferred to C57
Black background by backcrossing with C57BL/6J mice for ten
generations. Wild-type (WT) and homozygous mutant animals
(sdy/sdy; hereinafter referred to as sdy) used in the present study
were obtained by breeding of heterozygous parents and were
littermates. Genotype was determined by genomic polymerase
chain reaction (PCR) as reported by Cox et al. (2009). After
weaning, male mice were group housed (4 animals/cage) in a
semi enriched environment with 12 h:12 h light dark cycle with
lights on at 8.00 am and had ad-libitum food and tap-water.
Studies were conducted on age-matched adult (10--12 week old)
male WT and sdy mice.
Synaptoneurosomal Preparation and Drug
Treatments
Synaptoneurosomes were prepared according to the procedure
described by Kim et al. (2008). Briefly, the brains of mice
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were removed after decapitation, and the whole hippocampus
immediately dissected out using thick coronal slices (500 µm).
The tissue was homogenized using a glass-Teflon homogenizer
in 50 mM Hepes, pH 7.5, 125 mM NaCl, 100 mM sucrose,
2 mM potassium acetate and 0.2 mM sodium orthovanadate. The
homogenate was filtered through a series of nylon mesh filters
(149, 62, and 10 microns; Small Parts Inc). The final filtrate was
spun briefly (4,000 × g, 1 min) and the pellet was suspended in
the homogenizing buffer. This suspension was incubated with
1 µM tetrodotoxin, on ice for 5 min, followed by 5 min at room
temperature.
For mGluRI activation, synaptoneurosomal preparation from
each animal (n = 5--8 per genotype) was incubated with vehicle
(HEPES buffer) (no stimulation) or 5 µM of a specific mGluRI/5
agonist S-DHPG (hereinafter referred to as DHPG) for 2.5 min.
At the end of incubation, samples were instantly lysed in 1.2%
Triton x-100 and mixed with sample buffer (0.25 M Tris--HCl,
pH 6.8, 20% glycerol, 4% SDS, 10% β-mercaptoethanol) for
Western blotting using antibodies against signaling proteins
ERK1/2 or PKC. In a separate cohort of WT and sdy animals,
we assessed the time course of ERK1/2 activation by incubating
synaptoneurosomes for 0, 1, 2.5 and 5 min with subsaturating
(5 µM) and saturating (50 µM) concentrations of DHPG.
To assess if the impaired ERK phosphorylation in sdy mice
can be recovered by PAM of mGluR5, in another cohort
of animals (n = 4 each genotype), the synaptoneurosomal
preparations from WT and sdy mice were preincubated with
vehicle (0.5% methylcellulose) or CDPPB (5 µM, 15 min),
following which DHPG (5 µM) or vehicle was added and the
samples incubated for a further 2.5 min. The samples were
processed for Western blotting for p-ERK1/2 and β-actin as
described below.
Western Blotting
The procedures were essentially as described by us previously
(Bhardwaj et al., 2014). The control and DHPG-treated
synaptoneurosomal samples were electrophoresed and blot
transferred onto nitrocellulose membranes (Hybond ECL,
Amersham-Pharmacia Biotech). Themembranes were incubated
with 1:1000 dilution of rabbit polyclonal antibodies against
phospho-ERK1/2, total-ERK 1/2 or p-PKC. Following washes
in TBS--Tween-20, blots were incubated with anti-rabbit IgG-
horseradish peroxidase (HRP)-conjugated secondary antibodies.
To assess the expression levels of receptors mGluR1 and
mGluR5, samples from the unstimulated synaptoneurosomes
from WT and sdy mice (n = 5--6 per genotype) were Western
blotted with antibodies against mGluR1 (1:2500), or mGluR5
(1:1000). The blots were developed using chemiluminescence
detection system (Perkin-Elmer) and exposed to X-ray film
(Biomax XAR, Kodak). To account for variations in protein
loading, the blots were stripped in 62.5 mM Tris, 2% SDS
and 100 mM β-mercaptoethanol (pH 6.7) for 30 min at
50◦C and reprobed with a monoclonal anti-β-actin antibody
(1:5000). Antibody-labeling intensity (relative optical density,
ROD) was analyzed using a computerized image analysis
system (MCID-4, Imaging Research) and results are expressed
as ratio of RODs of specific protein to RODs of β-actin.
The data were analyzed using 2-way analysis of variance
(ANOVA) with genotype and DHPG treatment as independent
variables followed by post hoc Tukey’s test (significance at
p < 0.05). The data of receptor proteins (mGluR1 and
mGluR5) in WT and sdy animals were compared using the
student’s t-test.
Electrophysiological Recordings
Electrophysiological experiments were done essentially as
described by us previously (Bagot et al., 2012). WT and sdy
male mice (n = 4--5), 50--60 day-old were decapitated and
their brains were rapidly removed. Coronal slices containing the
hippocampal area (350 µm) were sectioned using a Vibratome
(Leica) in chilled (∼0--4◦C) oxygenated (95% O2/5% CO2) slice
cutting solution containing (in mM) sucrose 252, KCl 2.5,
MgCl2 4, CaCl2 0.1, KH2PO4 1.25, NaHCO3 26 and D-glucose
10. Freshly cut slices were placed in an incubating chamber with
carbogenated artificial cerebrospinal fluid (ACSF) composed of
the following (in mM): NaCl 125, KCl 2.5, NaHCO3 26, NaH2
PO4 1.25, MgCl2 1, CaCl2 2, and D-glucose 25 and recovered
at 32◦C for 1 h, followed by room temperature incubation
in ACSF before and during recording. All recordings were
performed in a submerged-type recording chamber that was
perfused with ACSF containing GABAA receptor antagonist
bicuculline (10 µM) at a flow rate of 1.5 ml/min to block
GABAA receptor-mediated inhibitory synaptic transmission.
Field excitatory postsynaptic potentials (fEPSPs) were evoked
by stimulating the Schaffer collateral pathway (constant current
pulses (0.08 ms) through a tungsten bipolar electrode (FHC)
and recorded by a glass pipette filled with ACSF in the stratum
radiatum of the CA1 region at least 60--80 µm away from
the cell body layer. Synaptic responses were evoked at 0.05 Hz
throughout, amplified and digitized by Multiclamp 700B and
Digidata 1400 respectively (Axon), and stored in a PC for offline
analysis using Clampfit (Axon). All recordings were performed at
room temperature. Slices displaying unstable baseline recording
were discarded. After obtaining a stable baseline for 30 min, LTD
was induced by a group I mGluR agonist DHPG. (37.5 µM,
applied for 10 min).
Novel Object Recognition (NOR) Memory
Our previously described procedure was followed (Bhardwaj
et al., 2009). Briefly, WT and sdy mice (n = 7--8/genotype)
were acclimatized for 20 min × 3d to a dark Plexiglas open-
field chamber (L × W × H: 45 × 45 × 45 cm) kept in a
dimly lit and noise-free room. NOR testing began next day
by injecting the mice with vehicle (0.5% methylcellulose, i.p.)
or the mGluR5 PAM CDPPB (10 mg/kg, i.p.). Thirty minutes
later the animals were introduced in the chamber with two
identical objects (small platic toys of various shapes, Dollar
Store). The dose of CDPPB was based on previous reports
on the efficacy of CDPPB in cognitive tasks (Uslaner et al.,
2009). The animals were allowed to explore the objects for
5 min (sample phase) after which they were placed back in
their respective home cages for 5 min (retention time for short-
term memory). At the end of retention time, the animals were
re-introduced to the chamber containing a novel object and
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a new copy of the familiar object used during the sample
phase. Animals were allowed to explore the objects for 5 min
(testing phase) and then returned to the home cage. To test
longer-term NOR memory, 24 h later, the mice again went
through similar sample and testing phases with a different novel
object and a new copy of the familiar object used during the
previous day’s sample phase. Behaviors during the sample and
testing phases were videotaped with an overhead recording
camera and the videos were scored for the time spent by the
animals exploring the two objects. A mouse was considered to
be involved in object exploration when its head was oriented
directly towards the object and within approximately 2--3 cm
from it. The time was also included if animal had at least one
forepaw on the object or was sniffing or licking the object. Object
recognition memory was defined as the ratio of exploration time
for the novel object (TN) over exploration time for the novel
plus familiar object (TF) (exploration ratio = TN/(TF + TN)).
Recognition memory above chance level (0.5) was analyzed
by ‘‘one-sample t-test’’ of the exploration ratio data. Group
differences in the exploration ratio as well as the total time
spent exploring both objects were analyzed using 2-way ANOVA
with genotype and drug treatments as independent variables,
followed by, if indicated, Tukey’s post hoc test (significance at
p< 0.05).
Spatial Learning and Memory in Morris Water
Maze (MWM)
A new cohort of WT and Sdy animals (n = 6--7 each group)
was used in this experiment. Our previously described MWM
procedure, modified for mice was employed to assess the effect
of CDPPB on spatial learning and memory (Wood et al., 2003).
The MWM for mice mouse water maze, consisting of a circular
pool (1.4m diameter and 36 cm high) with a removable plexiglass
platform (10 × 10 cm), was placed in a room with various
distal visual cues and a ceiling-mounted video recording camera.
The platform was hidden by the pool water (at 22--24◦C) made
opaque with a non-toxic paint. Animals were administered
saline or CDPPB (10 mg/kg, i.p.) and 30 min later released
in different quadrants of the pool in a pseudorandom order.
Animals’ latency to find the fixed and submerged platform was
analyzed by Water 2100 software. Each animal was given three
trials per day with an ITI of 1 h. Each trial lasted for 60 s
unless the animal reached the platform before. These spatial
learning trials were given for six consecutive days with drug
treatment each day, and the latency data was averaged. Two
hours after the last trial on the final day of training, spatial
memory was assessed in the pool without the platform with
3 trials of 60 s each from a different start location (probe test).
The time spent in the target quadrant and annulus crossing
of the platform location was analyzed. At the end of probe
trials, the platform was raised above the pool water and the
animals’ latency to find the visible platform and swim speed were
assessed for potential visual or locomotor impairments. Spatial
learning and probe test data were analyzed using 3-way repeated
measure and 2-way ANOVA respectively. Where indicated,
Tukey’s post hoc was used to determine significant differences
(p< 0.05).
FIGURE 1 | Western blot analysis of hippocampal mGluR1 and mGluR5
protein levels show no significant differences between wildtype (WT)
and dysbindin deficient (sdy) animals. Top panel show representative
immunoblots of mGluR1 (A), mGluR5 (B) and respective β-actin expression.
Lower panel shows relative optical density (ROD) ± SEM (n = 5--6 per
genotype) of mGluR1 (C) and mGluR5 (D) normalized to β-actin levels.
Results
Levels of mGluR1 and mGluR5 Proteins in
Hippocampal Synaptoneurosomes
Figure 1 shows representative Western blots and analyses of
protein levels of mGluR1 andmGluR5. ROD data (normalized to
β-actin) revealed no significant differences in either mGluR1 or
mGluR5 levels between WT and sdy mice (Student’s two-tailed
t-test t(9) = 1.471, p = 0.175 and t(9) = 0.192, p = 0.852 respectively
for mGluR1 and mGluR5).
Effect of mGluRI Activation on ERK1/2 and PKC
The levels of total and DHPG-activated ERK1/2 and PKC were
measured in hippocampal synaptoneurosomal preparations.
Figure 2A shows the representative Western blots and analyses
of total and phospho ERK1/2 levels in WT and sdy mice. A
two-way ANOVA showed no significant difference in the levels
of total ERK1/2 between WT and sdy animals either at the
basal level (i.e., vehicle) or after DHPG incubation (genotype:
F(1,24) = 0.0057, p = 0.981; DHPG treatment: F(1,24) = 0.099,
p = 0.756; genotype × DHPG interaction: F(1,24) = 0.042,
p = 0.839) (Figure 2B). However, analysis of P-ERK1/2 data
showed significant main effects of genotype (F(1,24) = 34.13,
p = 0.0001), DHPG treatment (F(1,24) = 18.60, p = 0.0002)
and genotype × DHPG interaction (F(1,24) = 22.22, p = 0.001)
(Figure 2C). As expected, DHPG induced significant increase
in P-ERK 1/2 in WT synaptoneurosomes; however, DHPG-
induced ERK1/2 phosphorylation was markedly attenuated in
the sdy animals. Impaired ERK1/2 phosphorylation in sdy
synaptoneurosomes was seen rapidly. For example, the difference
in p-ERK1/2 between WT and sdy animals is observed as
early as 1 min after DHPG application and persisted when
saturating concentrations of DHPG (50 µM) were used. A
two-way ANOVA of the data revealed a significant effect of
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FIGURE 2 | mGluR1-induced ERK1/2 phosphorylation in hippocampal
synaptoneurosomes in WT and sdy mice. Synaptoneurosomes were
incubated with a group I mGlu receptor agonist S-DHPG (5 µM) for 2.5 min at
room temp. (A) shows the representative Western blot signals using
antibodies specific for p-ERK 1/2, (total) t-ERK 1/2 and β-actin. DHPG
stimulation triggered significant ERK1/2 phosphorylation in WT but not in sdy
synaptoneurosomes. (V, vehicle; D, DHPG). (B,C) show ROD ± SEM of
t-ERK1/2 and p-ERK1/2 respectively (n = 5--8 per genotype). *p = 0.0015 WT
DHPG vs. WT vehicle (Tukey’s post hoc).
genotype (F(1,20) = 30.66, p = 0.0001), DHPG concentration
(F(4,20) = 7.47, p = 0.0001) and genotype × DHPG interaction
(F(4,20) = 2.66, p = 0.042) (Figure 3). Post hoc test showed
that ERK1/2 phosphorylation in Sdy mice increased at 50 µM
DHPG compared to 5 µM (p = 0.046) suggesting that increasing
the concentration of DHPG may overcome ERK1/2 deficits in
sdy mice. In order to find out if mGluRI signaling deficit in
sdy mice is specific to ERK1/2 pathway, we measured the level
of phospho-PKC in synaptoneurosomes incubated with DHPG.
The data showed a significant effect of DHPG treatment on
PKC phosphorylation (F(1,16) = 19.66, p = 0.0004); however,
no significant effect of the genotype (F(1,16) = 0.39, p = 0.539)
or genotype × DHPG interaction (F(1,16) = 0.63, p = 0.437)
was observed (Figure 4). In order to investigate if deficits
in ERK1/2 phosphorylation in sdy animals are ameliorated
by mGluR5 PAM CDPPB, synaptoneurosomes were incubated
with Vehicle, DHPG (5 µM), CDPPB (5 µM) or CDPPB
(5 µM) + DHPG (5 µM). Two way ANOVA of p-ERK1/2
data shows a significant effects of genotype (F(1,24) = 12.08,
p = 0.002), drug treatment (F(3,24) = 16.93, p = 0.0001) and
genotype × drug interaction (F(3,24) = 3.89, p = 0.021). Post
hoc showed significantly increased DHPG-induced p-ERK1/2 in
Sdy synaptoneurosome preincubated with CDPPB. This effect
of CDPPB was not observed in the WT synaptoneurosomes
(Figure 8).
mGluRI-Dependent LTD
Group 1 metabotropic glutamate receptors regulate excitatory
synaptic plasticity, in particular an NMDAR-independent form
of LTD (mGluRI-LTD) at CA1 excitatory synapses (Mukherjee
and Manahan-Vaughan, 2013). As ERK1/2 signaling pathway
is specifically implicated in this synaptic plasticity function of
FIGURE 3 | Impaired ERK1/2 activation by mGluRI stimulation is
observed rapidly at both sub-saturating (5 µM) and saturating (50 µM)
concentration of mGluRI agonist S-DHPG. (A) shows the representative
Western blot signals of p-ERK1/2, total (t)-ERK 1/2 and β-actin. (B) shows the
histogram of ROD of mean ± SEM (n = 6 per genotype) of the normalized
p-ERK1/2.
mGluRI (Gallagher et al., 2004), we asked whether mGluRI
hypofunctionality observed in sdy mice is also expressing at the
synaptic level. We compared DHPG-induced changes in fEPSP
recorded from the CA1 region between slices from WT and sdy
mice (Figure 5). While DHPG produced a robust LTD in WT
mice slices (percent depression of fEPSP slope at 60 min after
DHPG application: 18.1 ± 4.5%), it failed to induce significant
LTD in the sdy mice slices (0.3 ± 4.7%; WT vs. sdy: p = 0.045,
Student’s t-test).
Effect of mGluR5 Positive Allosteric Modulator
CDPPB on NOR
As studies show that enhancing mGluR5 transmission through
PAMs such as CDPPB, DFB and ADX47273 improve cognitive
functions and produce antipsychotic like effects in preclinical
models (Conn et al., 2009), we examined whether CDPPB-
induced enhancement of mGluR5 will ameliorate NOR memory
in sdy mice. Our previous data had shown a significant deficit
in short-term NOR memory in sdy mice (Bhardwaj et al.,
2009) which was confirmed in the present study. The present
results also show that pre-training administration of CDPPB
prevented short-term (5 min) object recognition memory deficit
in sdy mice (Figure 6). Two-way ANOVA of novel object
preference ratio indicated a significant main effect of genotype
(F(1,28) = 9.39, p = 0.004) and genotype × CDPPB interaction
(F(1,28) = 4.25, p = 0.048) in 5 min memory test (Figure 6A).
Post hoc tests confirmed the NOR deficit in sdy mice compared
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FIGURE 4 | No significant change in mGluR1-induced hippocampal
PKC phosphorylation between WT and sdy mice. Synaptoneurosomes
were incubated with 5 uM DHPG for 2.5 min at room temp. Phosphorylated
PKC (p-PKC) was measured by Western blots, using a pan p-PKC antibody.
(A) representative Western blot of the expression of phospho-PKC (p-PKC)
and β-actin from WT and Sdy mice (V, vehicle; D, DHPG). (B) mean + SEM
(n = 4--6 per genotype) of the ratio from p-PKC vs. β-actin. Two-way ANOVA
indicated the significant main effect of treatment only (*p = 0.032 WT DHPG
vs. WT vehicle; #:p = 0.009 sdy DHPG vs. sdy vehicle).
to the WT (p = 0.001). CDPPB treatment had no significant
effect in WT mice; however, CDPPB administered sdy mice
showed significantly better NOR performance compared to
vehicle treated sdy animals (p = 0.009). One-sample t-test of
the data also indicated that WT animals (both after vehicle or
CDPPB treatment) and sdy with CDPPB treatment preferentially
explore the novel object (significantly above 0.5 chance level).
ANOVA of 24 h NOR data showed no significant effect of
either genotype (F(1,27) = 2.68, p = 0.11) or genotype × CDPPB
interaction (F(1,27) = 0.30, p = 0.58) (Figure 6B). One-sample
t-test indicated a lack of significant effect of CDPPB on longer-
term NOR deficit in sdy mice. No significant effect of the
genotype or drug treatment was observed in the total exploration
time of the objects in both short and long-term NOR tests
(Figures 6C,D), indicating that the changes in NOR performance
in sdy mice or the effects of CDPPB are not due to the altered
general activity. We also separately confirmed the lack of effect
of CDPPB on locomotor activity by beam breaks in activity boxes
fitted with infra-red beams and sensors (Data not shown).
Effect of CDPPB on Spatial Learning and
Memory
A 3-way repeated measure ANOVA of spatial learning trials
showed a significant genotype × CDPPB × days interaction
(F(5,115) = 2.31, p = 0.04). Post hoc tests showed that sdy
animals have significant deficit in spatial learning as revealed
by a significantly higher latency to reach platform compared
FIGURE 5 | Scatter plots show decreased LTD of field excitatory
postsynaptic potential (fEPSP) induced by mGluRI agonist S-DHPG.
Hippocampal slices were incubated with 37.5 µM DHPG applied for 10 mins.
Recordings were done in a chamber perfused continuously by carbogenated
ACSF containing bicuculline methiodide (10 µM) to block GABAA
receptor-mediated inhibitory synaptic currents. fEPSPs were evoked by
stimulating the Schaffer collateral-commissural pathway via a constant current
pulse (0.08 ms) delivered through a tungsten bipolar electrode (FHC) at
0.05 Hz throughout and recorded by a glass pipette filled with ACSF in the
stratum radiatum of the CA1 region at least 60--80 µm away from the cell
body layer. Slices displaying unstable baseline recording were discarded. After
obtaining a stable baseline for 10 min, LTD was induced by S- DHPG.
(*p < 0.05, comparison of the average fEPSP slope between WT and sdy
mice, (n = 4--5), Student’s t test).
to WT animals (Figure 7A). CDPPB treatments significantly
improved the learning deficit in Sdy animals as their latency
across days of trials was not significantly different from the WT
animals. Analysis of spatial memory data (Figures 7B,C) showed
a significant genotype × CDPPB treatment interaction (Probe
test: F(1,23) = 4.59, p = 0.04; Annulus crossing: F(1,23) = 4.80,
p = 0.038). Post hoc tests confirmed spatial memory deficit
in sdy mice (sdy spent 22% of time in the target quadrant
compared to 57% of time spent by WT mice, p = 0.002).
CDPPB administration attenuated this spatial memory deficit
as no significant differences in the target quadrant preference
or annulus crossings were observed between sdy and WT
after CDPPB treatments. Finally, swim speed data in visible
platform test showed that genotype or CDPPB treatments had
no significant effect on visual or motor abilities of the mice
(Figure 7D).
Discussion
One of the principal findings of our study is that a loss of function
mutation in dtnbp1, a gene implicated in schizophrenia, in mice
leads to impaired intracellular signaling and synaptic plasticity
mediated by hippocampal group 1 metabotropic glutamate
receptors. The hypofunctionality of mGluRIs are related to
cognitive impairments due to dysbindin-1 deficiency, as a PAM
of mGluR5 was found to attenuate object recognition and spatial
learning andmemory deficits in sdymice.While previous studies
suggested a role of dysbindin-1 in NMDA receptor function
(Tang et al., 2009b; Karlsgodt et al., 2011), our study expands
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FIGURE 6 | NOR by WT and dysbindin mutants (sdy) animals
following 5 min and 24 h retention intervals. Both WT and sdy animals
were injected with either vehicle (Veh) or CDPPB (10 mg/kg, ip)
(n = 7--8/genotype/treatment), 30 min before the sample phase. In the
vehicle treated groups, novel object exploration ratio following 5 min
retention interval (A) indicates that sdy mice show less preference for the
novel object compared to WT controls (*p = 0.001). Administration of
CDPPB resulted in the rescue of NOR deficits in sdy mice (#p = 0.009
compared to sdy vehicle group) (A). At longer retention time (24 h), CDPPB
administration had no significant effect (B). (C,D) show that the total
exploration time of objects at 5 min and 24 h retention intervals respectively
are not significantly different between the groups.
the link between dysbindin-1 and glutamatergic transmission to
include mGluRI family.
Our data show that the decrease in ERK1/2 activation by
a specific mGluRI agonist in sdy hippocampus occurs in the
absence of significant changes in total protein levels of ERK1/2,
levels of mGluR1 or 5 proteins or alterations in basal or agonist-
induced PKC phosphorylation. The blunted ERK1/2 response
appears to be due to a reduced affinity of mGluRI for the
agonist, as increasing the concentration of DHPG partially
ameliorated the deficit. These findings suggest the possibility of a
role of dysbindin-1 in facilitating intracellular mGluRI receptor-
effector coupling. We do not know whether ERK1/2 deficit
is specific to the mGluR1 or the mGluR5 subtype of mGluRI
family; the resolution of this will depend on the availability
of specific agonists for mGluR1/mGluR5. However, given the
steep reduction in DHPG-induced ERK1/2 and the predominant
expression of mGluR5 subtype in the hippocampus (Romano
et al., 1996), we believe that at least a part of this deficit in
sdy animals, is due to mGluR5. We also do not know how the
loss of dysbindin-1 may induce changes in mGluRI signaling.
Dysbindin-1 functions are known to be mediated by binding to
several protein partners involved in membrane trafficking and
vesicle transport process (Guo et al., 2009). Whether dysbindin-1
interacts with mGluR1/5 proteins and modulates affinity of
glutamate for the receptor, or interacts with G-proteins or
signaling proteins upstream of ERK1/2 activation (e.g., src,
Ras, Rap1 or MEK) and affects receptor-effector coupling are
possibilities that remain to be explored. In regard to the
possibility of protein-protein interactions between dysbindin-1
and mGluRI components, it is notable that dysbindin-1 is
present at excitatory neuronal dendritic shafts and spines, sites
of mGluR1 and 5 expression (Talbot et al., 2009).
A related possibility is that dysbindin-1 mutation affects
membrane trafficking and endocytosis of mGluRIs in ways that
reduces surface expression of the receptor and/or uncouples
the receptor from specific signaling components (Dhami and
Ferguson, 2006). A role of dysbindin-1 in the endocytosis
and recycling of certain neurotransmitter receptors has been
previously suggested using dysbindin mutants and cell cultures.
For example, dysbindin-1 deficiency promotes diversion of
dopamine D2 receptor and NR2A subunit of NMDA receptor
from lysosomes to the cell surface (Ji et al., 2009; Tang
et al., 2009b). Since group I mGluRs are known to undergo
both agonist-dependent and -independent endocytosis in both
heterologous cell expression systems and primary neuronal
cultures (Dhami and Ferguson, 2006), it is possible that
dysbindin-1 modulates recycling of this receptor system
as well.
Our data show that impaired mGluRI-ERK1/2 signaling is
functionally relevant as it reduces mGluRI-dependent long-
term depression at the hippocampal CA1 excitatory synapses
of sdy mice. Our data in WT mice is consistent with the
reports that one of the most robust actions of the mGluRI
agonist DHPG is the induction of LTD of excitatory postsynaptic
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FIGURE 7 | Spatial learning and memory in MWM. WT and sdy animals
were injected with either vehicle (Veh) or CDPPB (10 mg/kg, ip), (n = 6--7 per
genotype/treatment) once a day, for 6 days, 30 min before the first trial of the
day in. (A) Escape latency (seconds) during hidden platform location for WT
and sdy animals following either vehicle or CDPPB administration. Sdy-vehicle
animals have significant deficit in spatial learning compared to WT-vehicle
animals on days 5 and 6 (*p < 0.05). CDPPB treatments significantly
improved the learning deficit in sdy animals compared to vehicle treated sdy
animals (#p < 0.05). (B) Time spent in the target quadrant in the probe test.
Vehicle treated sdy mice showed a significant deficit compared to vehicle
treated WT mice in the time spent in correct quadrant (**p = 0.002). CDPPB
treatment attenuated this spatial memory deficit in sdy mice as no significant
differences in the target quadrant preference was observed between sdy and
WT CDPPB treated animals. (C) Average annulus crossings during probe trial
for all animals. Similar to target quadrant preference, annulus crossings also
revealed a significant deficit in spatial memory in sdy mice and its amelioration
by CDPPB (**p = 0.0012, vehicle treated sdy mice compared to vehicle
treated WT mice; (&p = 0.042, sdy CDPPB vs. sdy vehicle. (D) Visible platform
data revealed no significant differences in mean swim speed among
experimental groups.
potentials in CA1 pyramidal neurons (Gladding et al., 2009;
Mukherjee and Manahan-Vaughan, 2013). However, it should
be noted that group I mGluRs have also been implicated in
LTP formation in both pyramidal neurons and interneurons
in the hippocampus (for review, see Anwyl, 2009). Since the
induction of LTD by DHPG is known to involve the signaling
pathway of ERK1/2 MAP kinase (Gallagher et al., 2004), we
hypothesized that hippocampal DHPG-induced LTD will be
significantly reduced in dysbindin mutants because of potential
receptor uncoupling. The results support our hypothesis since
we found that DHPG-induced LTD at CA1 was smaller in
magnitude and shorter in duration in sdy mice than WT
controls. Our findings also underscore the point that the
impact of sdy mutation could be specific to the mGluRI-
mediated form of LTD, since the NMDAR-mediated LTD was
reported to be unaffected in sdy mice (Tang et al., 2009b).
In the same study, Tang et al. have shown that NMDAR-
mediated LTP was facilitated in sdy mice, which suggests
enhanced hippocampus-dependent cognitive functions in these
mice. Notably, mGluRI-LTD is implicated in hippocampus-
dependent cognitive processes such as novelty encoding,
object place configurations and recognition (Braunewell and
Manahan-Vaughan, 2001; Kemp and Manahan-Vaughan, 2004;
Popkirov and Manahan-Vaughan, 2010). Our findings that sdy
mice displayed impairment in most hippocampus-dependent
cognitive tasks therefore support the importance of intact
mGluR-LTD for these cognitive processes.
We focused on NOR and spatial earning in MWM as
performance in these behaviors requires hippocampal network,
and they are relevant to cognitive phenotype of schizophrenia.
They are components of preclinical assays suggested by the
Measurement and Treatment Research to Improve Cognition
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FIGURE 8 | Pretreatment with CDPPB partially normalizes
DHPG-induced ERK1/2 deficit in Sdy mice. Percent increase in
βactin-normalized p-ERK1/2 in synaptoneurosomes incubated with CDPPB
(C, 5µM, 15 min) without or with DHPG (D, 5µM 2.5 min) (*p = 0.043
compared to Sdy DHPG; n = 4 per genotype).
in Schizophrenia (MATRICS) initiative (Young et al., 2009).
Schizophrenia patients show deficits in a number of cognitive
domains including working declarative and visuso-spatial
memory that can be partially modeled in rodents. NOR task
models certain components of declarative memory in rodents by
measuring spontaneous preference of rodents to explore a novel
object (Ennaceur, 2010), whereas the MWM task interrogates
hippocampal-dependent visual learning and memory (D’Hooge
and De Deyn, 2001). Our findings of amelioration of object
recognition and spatial learning and memory deficits in sdy mice
by pre-treatment with mGluR5 PAM CDPPB suggest that group
1 GluR abnormality contributes, at least in part, to cognitive
dysfunctions caused by dysbindin deficiency. Our data show
that pre-training acute administration of CDPPB, rescued short-
term (5 min) but not long-term (24 h) memory deficit in sdy
mice. The differential effect of CDPPB on short vs. longer-
term object recognition memory deficit could be related to the
dose of the drug used or its plasma half-life (approximately
4 h). For MWM learning, animals were pretreated with CDPPB
every day before putting them in the maze. Thus, the long-term
memory improvement in this task appears be due to a chronic
effect of CDPPB on learning performance. These data highlight
differential acute vs. chronic effects of CDPPB and support a
growing number of evidence that mGluR5 PAMs have robust
efficacy in a range of learning and memory in preclinical models
of schizophrenia (Liu et al., 2008; Conn et al., 2009; Homayoun
and Moghaddam, 2010).
Our studies show that the dose of CDPPB used (10 mg/kg,
i.p.), while improving object recognition and spatial memory
in sdy animals, has no significant effect in the WT mice.
This lack of effect of CDPPB in control mice is apparently
inconsistent with previous studies that show improvement in
object recognition in rats and spatial learning in mice by 3
and 30 mg/kg (i.p.) CDPPB respectively (Uslaner et al., 2009;
Fowler et al., 2013). Thus, it seems that the effect of this mGluR5
PAM is dependent on the dose of the compound used, animal
species and the behavioral task in question. The mechanism by
which CDPPB attenuated memory deficits in sdy mice is not
addressed in our studies. CDPPB is an allosteric activator of
mGluR5 and enhances the efficacy of the physiological level of
glutamate on mGluR5 receptor (Niswender and Conn, 2010).
Since we noticed an enhancement of DHPG-induced p-ERK1/2
levels in Sdy hippocampus, we believe that the mGluRI-ERK1/2
deficit in sdy is possibly due to reduced agonist affinity of
the receptors. Since ERK1/2 has been implicated in mGluR1/5-
dependent LTD (Gallagher et al., 2004), we speculate that the
rescue of behaviors in sdy mice by CDPPB might be due to
normalized LTD. However, this idea needs to experimentally
tested.
Several genetic variations associated with schizophrenia
map on to cognitive phenotypes; however, the mechanisms
of genetic abnormality and cognition are poorly understood.
Metabotropic glutamate receptors have been implicated in
schizophrenia and impaired mGluR1/5 function leads to a
number of learning and memory deficits (Conquet et al.,
1994; Lu et al., 1997). We believe that our novel finding that
dysbindin-1-deficiency leads to a behaviorally significant state
of mGluRI hypofunction provides a link between dysbindin-1
gene variations, glutamatergic transmission and cognitive
dysfunctions in schizophrenia.
Acknowledgments
This study was supported by a Canadian Institute of Health
Research (CIHR) grant to LKS.
Abbreviations
CDPPB, 3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl benzamide;
ERK1/2, extracellular signal regulated kinase 1/2; DHPG, [(S)-
3, 5-dihydroxyphenylglycine]; mGluR, metabotropic glutamate
receptor.
References
Anwyl, R. (2009). Metabotropic glutamate receptor-dependent long-term
potentiation. Neuropharmacology 56, 735--740. doi: 10.1016/j.neuropharm.
2009.01.002
Bagot, R. C., Tse, Y. C., Nguyen, H. B., Wong, A. S., Meaney, M. J., and Wong,
T. P. (2012). Maternal care influences hippocampal N-methyl-D-aspartate
receptor function and dynamic regulation by corticosterone in adulthood. Biol.
Psychiatry 72, 491--498. doi: 10.1016/j.biopsych.2012.03.016
Bhardwaj, S. K., Baharnoori, M., Sharif-Askari, B., Kamath, A., Williams, S.,
and Srivastava, L. K. (2009). Behavioral characterization of dysbindin-1
deficient sandy mice. Behav. Brain Res. 197, 435--441. doi: 10.1016/j.bbr.2008.
10.011
Bhardwaj, S. K., Tse, Y. C., Ryan, R., Wong, T. P., and Srivastava, L. K. (2014).
Impaired adrenergic-mediated plasticity of prefrontal cortical glutamate
synapses in rats with developmental disruption of the ventral hippocampus.
Neuropsychopharmacology 39, 2963--2973. doi: 10.1038/npp.2014.142
Braunewell, K. H., and Manahan-Vaughan, D. (2001). Long-term depression: a
cellular basis for learning? Rev. Neurosci. 12, 121--140. doi: 10.1515/revneuro.
2001.12.2.121
Burdick, K. E., Goldberg, T. E., Funke, B., Bates, J. A., Lencz, T., Kucherlapati,
R., et al. (2007). DTNBP1 genotype influences cognitive decline in
Frontiers in Behavioral Neuroscience | www.frontiersin.org 9 March 2015 | Volume 9 | Article 72
Bhardwaj et al. Dysbindin and metabotropic glutamate receptors
schizophrenia. Schizophr. Res. 89, 169--172. doi: 10.1016/j.schres.2006.
09.008
Conn, P. J., Lindsley, C. W., and Jones, C. K. (2009). Activation of metabotropic
glutamate receptors as a novel approach for the treatment of schizophrenia.
Trends Pharmacol. Sci. 30, 25--31. doi: 10.1016/j.tips.2008.10.006
Conquet, F., Bashir, Z. I., Davies, C. H., Daniel, H., Ferraguti, F., Bordi, F., et al.
(1994). Motor deficit and impairment of synaptic plasticity in mice lacking
mGluR1. Nature 372, 237--243. doi: 10.1038/372237a0
Cox, M. M., Tucker, A. M., Tang, J., Talbot, K., Richer, D. C., Yeh, L., et al.
(2009). Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on
a C57BL/6J genetic background. Genes Brain Behav. 8, 390--397. doi: 10.1111/j.
1601-183x.2009.00477.x
Coyle, J. T. (2012). NMDA Receptor and schizophrenia: a brief history. Schizophr.
Bull. 38, 920--926. doi: 10.1093/schbul/sbs076
Dhami, G. K., and Ferguson, S. S. G. (2006). Regulation of metabotropic glutamate
receptor signaling, desensitization and endocytosis. Pharmacol. Ther. 111,
260--271. doi: 10.1016/j.pharmthera.2005.01.008
D’Hooge, R., and De Deyn, P. P. (2001). Applications of the Morris water maze in
the study of learning and memory. Brain Res. Brain Res. Rev. 36, 60--90. doi: 10.
1016/s0165-0173(01)00067-4
Ennaceur, A. (2010). One-trial object recognition in rats andmice: methodological
and theoretical issues. Behav. Brain Res. 215, 244--254. doi: 10.1016/j.bbr.2009.
12.036
Fallgatter, A. J., Ehlis, A. C., Herrmann, M. J., Hohoff, C., Reif, A., Freitag, C. M.,
et al. (2010). DTNBP1 (dysbindin) gene variants modulate prefrontal brain
function in schizophrenic patients---support for the glutamate hypothesis of
schizophrenias. Genes Brain Behav. 9, 489--497. doi: 10.1111/j.1601-183x.2010.
00574.x
Ferraguti, F., Crepaldi, L., and Nicoletti, F. (2008). Metabotropic glutamate 1
receptor: current concepts and perspectives. Pharmacol. Rev. 60, 536--581.
doi: 10.1124/pr.108.000166
Fowler, S. W., Ramsey, A. K., Walker, J. M., Serfozo, P., Olive, M. F., Schachtman,
T. R., et al. (2011). Functional interaction of mGlu5 and NMDA receptors in
aversive learning in rats. Neurobiol. Learn. Mem. 95, 73--79. doi: 10.1016/j.nlm.
2010.11.009
Fowler, S. W., Walker, J. M., Klakotskaia, D., Will, M. J., Serfozo, P., Simonyi, A.,
et al. (2013). Effects of a metabotropic glutamate receptor 5 positive allosteric
modulator, CDPPB, on spatial learning task performance in rodents.Neurobiol.
Learn. Mem. 99, 25--31. doi: 10.1016/j.nlm.2012.10.010
Gallagher, S. M., Daly, C. A., Bear, M. F., and Huber, K. M. (2004). Extracellular
signal-regulated protein kinase activation is required for metabotropic
glutamate receptor-dependent long-term depression in hippocampal area CA1.
J. Neurosci. 24, 4859--4864. doi: 10.1523/jneurosci.5407-03.2004
Ghiani, C. A., Starcevic, M., Rodriguez-Fernandez, I. A., Nazarian, R., Cheli,
V. T., Chan, L. N., et al. (2010). The dysbindin-containing complex (BLOC-
1) in brain: developmental regulation, interaction with SNARE proteins
and role in neurite outgrowth. Mol. Psychiatry 115, 204--215. doi: 10.1038/
mp.2009.58
Gladding, C. M., Fitzjohn, S. M., and Molnár, E. (2009). Metabotropic glutamate
receptor-mediated long-term depression: molecular mechanisms. Pharmacol.
Rev. 61, 395--412. doi: 10.1124/pr.109.001735
Guo, A. Y., Sun, J., Riley, B. P., Thiselton, D. L., Kendler, K. S., and Zhao, Z.
(2009). The dystrobrevin-binding protein 1 gene: features and networks. Mol.
Psychiatry 14, 18--29. doi: 10.1038/mp.2008.88
Hattori, S., Murotani, T., Matsuzaki, S., Ishizuka, T., Kumamoto, N., Takeda,
M., et al. (2008). Behavioral abnormalities and dopamine reductions in sdy
mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia.
Biochem. Biophys. Res. Commun. 373, 298--302. doi: 10.1016/j.bbrc.2008.
06.016
Homayoun, H., and Moghaddam, B. (2010). Group 5 metabotropic glutamate
receptors: role in modulating cortical activity and relevance to cognition. Eur.
J. Pharmacol. 639, 33--39. doi: 10.1016/j.ejphar.2009.12.042
Jentsch, J. D., Trantham-Davidson, H., Jairl, C., Tinsley, M., Cannon, T. D.,
and Lavin, A. (2009). Dysbindin modulates prefrontal cortical glutamatergic
circuits and working memory function in mice. Neuropsychopharmacology 34,
2601--2608. doi: 10.1038/npp.2009.90
Ji, Y., Yang, F., Papaleo, F., Wang, H. X., Gao, W. J., Weinberger, D. R., et al.
(2009). Role of dysbindin in dopamine receptor trafficking and cortical GABA
function. Proc. Natl. Acad. Sci. U S A 106, 19593--19598. doi: 10.1073/pnas.
0904289106
Kalkstein, S., Hurford, I., and Gur, R. C. (2010). Neurocognition in schizophrenia.
Curr. Top. Behav. Neurosci. 4, 373--390. doi: 10.1007/7854_2010_42
Karlsgodt, K. H., Robleto, K., Trantham-Davidson, H., Jairl, C., Cannon, T. D.,
Lavin, A., et al. (2011). Reduced dysbindin expression mediates N-methyl-D-
aspartate receptor hypofunction and impaired working memory performance.
Biol. Psychiatry 69, 28--34. doi: 10.1016/j.biopsych.2010.09.012
Kemp, A., andManahan-Vaughan, D. (2004). Hippocampal long-term depression
and long-term potentiation encode different aspects of novelty acquisition.
Proc. Natl. Acad. Sci. U S A 101, 8192--8197. doi: 10.1073/pnas.0402650101
Kim, S. H., Markham, J. A., Weiler, I. J., and Greenough, W. T. (2008). Aberrant
early-phase ERK inactivation impedes neuronal function in fragile X syndrome.
Proc. Natl. Acad. Sci. U S A 105, 4429--4434. doi: 10.1073/pnas.0800257105
Li, W., Zhang, Q., Oiso, N., Novak, E. K., Gautam, R., O’brien, E. P., et al. (2003).
Hermansky-Pudlak syndrome type 7 (HPS-7) results frommutant dysbindin, a
member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1).
Nat. Genet. 35, 84--89. doi: 10.1038/ng1229
Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., et al. (2008).
ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-
yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor
5-selective positive allosteric modulator with preclinical antipsychotic-like and
procognitive activities. J. Pharmacol. Exp. Ther. 327, 827--839. doi: 10.1124/jpet.
108.136580
Lu, Y. M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M.,
et al. (1997). Mice lacking metabotropic glutamate receptor 5 show impaired
learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP.
J. Neurosci. 17, 5196--5205.
Mukherjee, S., and Manahan-Vaughan, D. (2013). Role of metabotropic
glutamate receptors in persistent forms of hippocampal plasticity and learning.
Neuropharmacology 66, 65--81. doi: 10.1016/j.neuropharm.2012.06.005
Niswender, C. M., and Conn, P. J. (2010). Metabotropic glutamate receptors:
physiology, pharmacology and disease. Annu. Rev. Pharmacol. Toxicol. 50,
295--322. doi: 10.1146/annurev.pharmtox.011008.145533
Papaleo, F., Yang, F., Garcia, S., Chen, J., Lu, B., Crawley, J. N., et al. (2012).
Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like
behaviors via dopamine/D2 pathways. Mol. Psychiatry 17, 85--98. doi: 10.
1038/mp.2010.106
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V.,
et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat
schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13, 1102--1107.
doi: 10.1038/nm1632
Popkirov, S. G., and Manahan-Vaughan, D. (2010). Involvement of the
metabotropic glutamate receptor mGluR5 in NMDA receptor-dependent,
learning-facilitated long-term depression in CA1 synapses. Cereb. Cortex 21,
501--509. doi: 10.1093/cercor/bhq093
Romano, C., Van Den Pol, A. N., and O’malley, K. L. (1996). Enhanced early
developmental expression of the metabotropic glutamate receptor mGluR5 in
rat brain: protein, mRNA splice variants, and regional distribution. J. Comp.
Neurol. 367, 403--412. doi: 10.1002/(sici)1096-9861(19960408)367:3<403::aid-
cne6>3.0.co;2-9
Straub, R. E., Jiang, Y., Maclean, C. J., Ma, Y., Webb, B. T., Myakishev, M. V., et al.
(2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of
themouse dysbindin gene, is associated with schizophrenia.Am. J. Hum. Genet.
71, 337--348. doi: 10.1086/341750
Swank, R. T., Sweet, H. O., Davisson, M. T., Reddington, M., and Novak, E. K.
(1991). Sandy: a new mouse model for platelet storage pool deficiency. Genet.
Res. 58, 51--62. doi: 10.1017/s0016672300029608
Talbot, K., Ong, W. Y., Blake, D. J., Tang, J., Louneva, N., Carlson, G. C., et al.
(2009). ‘‘Dysbindin-1 and its protein family,’’ in Handbook of Neurochemistry
and Molecular Neurobiology 3rd Edn. eds D. C. Javitt and J. Kantrowitz (New
York: Springer Science), 107--241.
Tang, J., Legros, R. P., Louneva, N., Yeh, L., Cohen, J. W., Hahn, C. G., et al.
(2009a). Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases
is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA
expression. Hum. Mol. Genet. 18, 3851--3863. doi: 10.1093/hmg/ddp329
Tang, T. T., Yang, F., Chen, B. S., Lu, Y., Ji, Y., Roche, K. W., et al. (2009b).
Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface
Frontiers in Behavioral Neuroscience | www.frontiersin.org 10 March 2015 | Volume 9 | Article 72
Bhardwaj et al. Dysbindin and metabotropic glutamate receptors
expression. Proc. Natl. Acad. Sci. U S A 106, 21395--21400. doi: 10.1073/pnas.
0910499106
Uslaner, J. M., Parmentier-Batteur, S., Flick, R. B., Surles, N. O., Lam, J. S.,
Mcnaughton, C. H., et al. (2009). Dose-dependent effect of CDPPB, the
mGluR5 positive allosteric modulator, on recognition memory is associated
with GluR1 and CREB phosphorylation in the prefrontal cortex and
hippocampus. Neuropharmacology 57, 531--538. doi: 10.1016/j.neuropharm.
2009.07.022
Volk, D. W., Eggan, S. M., and Lewis, D. A. (2010). Alterations in metabotropic
glutamate receptor 1alpha and regulator of G protein signaling 4 in the
prefrontal cortex in schizophrenia. Am. J. Psychiatry 167, 1489--1498. doi: 10.
1176/appi.ajp.2010.10030318
Weickert, C. S., Rothmond, D. A., Hyde, T. M., Kleinman, J. E., and Straub, R. E.
(2008). Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation
of schizophrenia patients. Schizophr. Res. 98, 105--110. doi: 10.1016/j.schres.
2007.05.041
Wood, G. K., Quirion, R., and Srivastava, L. K. (2003). Early environment
contributes to developmental disruption of MPFC after neonatal ventral
hippocampal lesions in rats. Synapse 50, 223--232. doi: 10.1002/syn.10265
Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., and Geyer, M. A.
(2009). Using the MATRICS to guide development of a preclinical cognitive
test battery for research in schizophrenia. Pharmacol. Ther. 122, 150--202.
doi: 10.1016/j.pharmthera.2009.02.004
Zhang, J. P., Burdick, K. E., Lencz, T., andMalhotra, A. K. (2010). Meta-analysis of
genetic variation in DTNBP1 and general cognitive ability. Biol. Psychiatry 68,
1126--1133. doi: 10.1016/j.biopsych.2010.09.016
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Bhardwaj, Ryan, Wong and Srivastava. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution and reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 11 March 2015 | Volume 9 | Article 72
